$IGC
IGC Pharma Inc Stock $igc

$igc Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000118518523000796 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023 Q1
Revenue	$291.0K	$555.0K	$166.0K
YoY Change	44.06%	161.79%	36.07%
Cost Of Revenue	$117.0K	$300.0K	$103.0K
YoY Change	74.63%	328.57%	90.74%
Gross Profit	$174.0K	$255.0K	$63.00K
YoY Change	28.89%	79.58%	-7.35%
Gross Profit Margin	59.79%	45.95%	37.95%
Selling, General & Admin	$1.397M	$1.647M	$3.233M
YoY Change	-24.69%	6.26%	-39.41%
% of Gross Profit	802.87%	645.88%	5131.75%
Research & Development	$1.268M	$747.0K	$493.0K
YoY Change	65.1%	-46.41%	-60.02%
% of Gross Profit	728.74%	292.94%	782.54%
Depreciation & Amortization	$140.0K	$155.0K	$153.0K
YoY Change	-10.26%	-4.32%	-7.27%
% of Gross Profit	80.46%	60.78%	242.86%
Operating Expenses	$2.665M	$2.394M	$3.726M
YoY Change	1.6%	-18.68%	-43.28%
Operating Profit	-$2.491M	-$2.139M	-$3.663M
YoY Change	0.12%	-23.66%	-43.65%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$40.00K	$64.00K	$9.000K
YoY Change	-13.04%	276.47%	-10.0%
Pretax Income	-$2.451M	-$2.075M	-$4.030M
YoY Change	0.37%	-25.49%	-38.03%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.451M	-$2.075M	-$4.030M
YoY Change	0.37%	-25.49%	-38.03%
Net Earnings / Revenue	-842.27%	-373.87%	-2427.71%
Basic Earnings Per Share	-$0.05
Diluted Earnings Per Share	-$0.05	-$0.04	-$0.08
COMMON SHARES
Basic Shares Outstanding	53.92M shares	53.08M shares	53.08M shares
Diluted Shares Outstanding	54.30M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.120M	$1.950M	$3.350M
YoY Change	-54.23%	-75.79%	-67.97%
Cash & Equivalents	$3.026M	$1.723M	$3.196M
Short-Term Investments	$100.0K	$227.0K	$154.0K
Other Short-Term Assets	$143.0K	$193.0K	$334.0K
YoY Change	0.0%	-23.11%	-0.6%
Inventory	$2.636M	$2.641M	$2.651M
Prepaid Expenses
Receivables	$137.0K	$225.0K	$107.0K
Other Receivables	$10.00K	$0.00	$24.00K
Total Short-Term Assets	$6.117M	$5.078M	$6.466M
YoY Change	-45.38%	-60.1%	-57.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.947M	$8.104M	$8.539M
YoY Change	-6.17%	-11.54%	-9.34%
Goodwill
YoY Change
Intangibles	$1.181M	$1.179M	$1.170M
YoY Change	24.05%	25.83%	27.59%
Long-Term Investments
YoY Change
Other Assets	$998.0K	$1.017M	$1.003M
YoY Change	5.05%	10.3%	7.04%
Total Long-Term Assets	$10.39M	$10.60M	$10.71M
YoY Change	-3.44%	-7.38%	-8.62%
TOTAL ASSETS
Total Short-Term Assets	$6.117M	$5.078M	$6.466M
Total Long-Term Assets	$10.39M	$10.60M	$10.71M
Total Assets	$16.51M	$15.67M	$17.18M
YoY Change	-24.83%	-35.14%	-35.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$549.0K	$672.0K	$530.0K
YoY Change	20.39%	47.37%	-45.97%
Accrued Expenses	$1.557M	$1.459M	$752.0K
YoY Change	68.14%	21.58%	-48.39%
Deferred Revenue
YoY Change
Short-Term Debt	$3.000K	$3.000K	$0.00
YoY Change	0.0%	0.0%	-100.0%
Long-Term Debt Due	$0.00	$3.000K	$3.000K
YoY Change	-100.0%	0.0%	0.0%
Total Short-Term Liabilities	$2.106M	$2.131M	$1.898M
YoY Change	52.39%	28.45%	-22.24%
LONG-TERM LIABILITIES
Long-Term Debt	$139.0K	$140.0K	$141.0K
YoY Change	-2.11%	-2.1%	-2.08%
Other Long-Term Liabilities	$17.00K	$21.00K	$228.0K
YoY Change	13.33%	31.25%	1325.0%
Total Long-Term Liabilities	$302.0K	$340.0K	$369.0K
YoY Change	-30.09%	-27.19%	-26.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.106M	$2.131M	$1.898M
Total Long-Term Liabilities	$302.0K	$340.0K	$369.0K
Total Liabilities	$2.408M	$2.471M	$2.267M
YoY Change	32.75%	16.23%	-22.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$105.2M	-$102.7M	-$100.7M
YoY Change	11.45%	11.74%	12.91%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.10M	$13.20M	$14.91M
YoY Change
Total Liabilities & Shareholders Equity	$16.51M	$15.67M	$17.18M
YoY Change	-24.83%	-35.14%	-35.98%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.451M	-$2.075M	-$4.030M
YoY Change	0.37%	-25.49%	-38.03%
Depreciation, Depletion And Amortization	$140.0K	$155.0K	$153.0K
YoY Change	-10.26%	-4.32%	-7.27%
Cash From Operating Activities	-$1.620M	-$1.468M	-$1.517M
YoY Change	-3.91%	-33.15%	71.03%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$20.00K	$475.0K
YoY Change	-48.98%	-84.25%	-185.9%
Acquisitions
YoY Change
Other Investing Activities	$130.0K	$43.00K	$233.0K
YoY Change	54.76%
Cash From Investing Activities	$80.00K	-$5.000K	-$242.0K
YoY Change	-56.04%	-96.84%	-56.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.860M	-$1.000K	-1.000K
YoY Change	2703.92%	0.0%	0.0%
NET CHANGE
Cash From Operating Activities	-1.620M	-$1.468M	-1.517M
Cash From Investing Activities	80.00K	-$5.000K	-242.0K
Cash From Financing Activities	2.860M	-$1.000K	-1.000K
Net Change In Cash	1.320M	-$1.473M	-1.760M
YoY Change	-194.15%	-38.8%	22.14%
FREE CASH FLOW
Cash From Operating Activities	-$1.620M	-$1.468M	-$1.517M
Capital Expenditures	$50.00K	$20.00K	$475.0K
Free Cash Flow	-$1.670M	-$1.488M	-$1.992M
YoY Change	-6.39%	-35.94%	496.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	dei	Document Type DocumentType	10-Q
CY2023Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	dei	Entity File Number EntityFileNumber	001-32830
CY2023Q2	dei	Entity Registrant Name EntityRegistrantName	IGC PHARMA, INC.
CY2023Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MD
CY2023Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2760393
CY2023Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	10224 Falls Road
CY2023Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Potomac
CY2023Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20854
CY2023Q2	dei	City Area Code CityAreaCode	301
CY2023Q2	dei	Local Phone Number LocalPhoneNumber	983-0998
CY2023Q2	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q2	dei	Trading Symbol TradingSymbol	IGC
CY2023Q2	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q2	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53916604	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1723000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3196000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	225000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	107000	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	227000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	154000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2641000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2651000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	262000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	358000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5078000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6466000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1179000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1170000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8104000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8213000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1017000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1003000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	295000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	326000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	10595000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	10712000	usd
CY2023Q2	us-gaap	Assets Assets	15673000	usd
CY2023Q1	us-gaap	Assets Assets	17178000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	672000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	530000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1459000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1368000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2131000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1898000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	140000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	141000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	179000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	340000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	369000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2471000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2267000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53077436	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53077436	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53077436	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53077436	shares
CY2023Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	119322000	usd
CY2023Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	118965000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3380000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3389000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102740000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100665000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13202000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14911000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15673000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17178000	usd
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2022Q2	us-gaap	Revenues Revenues	212000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	300000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	70000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	255000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	142000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1647000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1550000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	747000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1394000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2139000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2802000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2075000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2785000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2075000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2785000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-219000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2066000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3004000	usd
CY2023Q2	igc	Earnings Per Share Basic Diluted EarningsPerShareBasicDiluted	-0.04
CY2022Q2	igc	Earnings Per Share Basic Diluted EarningsPerShareBasicDiluted	-0.05
CY2023Q2	igc	Weighted Average Number Of Share Outstanding Basic Diluted WeightedAverageNumberOfShareOutstandingBasicDiluted	53077436	shares
CY2022Q2	igc	Weighted Average Number Of Share Outstanding Basic Diluted WeightedAverageNumberOfShareOutstandingBasicDiluted	51616598	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	23892000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1152000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2785000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-219000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	22040000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14911000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	357000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2075000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	9000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13202000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2075000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2785000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	155000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	162000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	357000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1152000	usd
CY2023Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	53000	usd
CY2022Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-68000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	118000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10000	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	74000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-33000	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-73000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	13000	usd
CY2022Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-15000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	142000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-524000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	91000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-258000	usd
CY2023Q2	igc	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-31000	usd
CY2022Q2	igc	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-31000	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-28000	usd
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-33000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1468000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2196000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20000	usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	127000	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	43000	usd
CY2022Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	28000	usd
CY2022Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	31000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-158000	usd
CY2023Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2022Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-1000	usd
CY2022Q2	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-1000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1000	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-52000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1473000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2407000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3196000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10460000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1723000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8053000	usd
CY2023Q2	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	357000	usd
CY2022Q2	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	1152000	usd
CY2023Q2	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 1 </b>–<b> BUSINESS DESCRIPTION</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IGC Pharma, Inc., is a clinical-stage pharmaceutical company with a diversified revenue model that develops prescription drugs and over-the-counter (OTC) products. We are a Maryland corporation established in 2005 with a fiscal year that is a 52- or 53-week period that ends on March 31.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our focus is on developing innovative therapies for neurological disorders such as Alzheimer’s disease, epilepsy, Tourette syndrome, and sleep disorders. We also focus on formulations for eating disorders, chronic pain, premenstrual syndrome (PMS), and dysmenorrhea, in addition to health and wellness OTC formulations. The Company is developing its proprietary lead candidate, IGC-AD1, an investigational oral therapy for the treatment of agitation associated with Alzheimer’s disease. IGC-AD1 is currently in Phase 2 (Phase 2B) clinical trials after completing nearly a decade of research and realizing positive results from pre-clinical and a Phase 1 trial. This previous research into IGC-AD1 has demonstrated efficacy in reducing plaques and tangles, which are two important hallmarks of Alzheimer’s, as well as reducing neuropsychiatric symptoms associated with dementia in Alzheimer’s disease, such as agitation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>IGC has two segments: Life Sciences and Infrastructure.</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Life Sciences Segment</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i><span style="text-decoration:underline">Pharmaceutical</span></i>: Since 2014, the Company has focused primarily on the potential uses of phytocannabinoids, in combination with other compounds, to treat multiple diseases, such as Alzheimer’s disease. As a company engaged in the clinical-stage pharmaceutical industry, we focus our research and development efforts, subject to results of future clinical trials, on seeking pharmaceutical solutions that may a) alleviate neuropsychiatric symptoms such as agitation, anxiety, and depression associated with dementia in Alzheimer’s disease; and b) halt the onset, progression, or cure Alzheimer’s disease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="text-decoration:underline">The Company currently has two main investigational small molecules in various stages of development:</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">1) <b>IGC-AD1</b>, our proprietary lead therapeutic candidate, is a Tetrahydrocannabinol (THC) based formulation that has demonstrated in Alzheimer’s cell lines the potential to reduce the buildup of Aβ plaques and the potential to decrease or inhibit the phosphorylation of tau, a protein that is responsible for the formation of neurofibrillary tangles (NFTs), both important hallmarks of Alzheimer’s. In addition, Phase 1 human trial results demonstrated IGC-AD1’s potential to reduce agitation in dementia due to Alzheimer’s. IGC-AD1 is currently in Phase 2B trials for treating agitation in dementia from Alzheimer’s, a condition that affects over 10 million individuals in North America and Europe, and</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">2) <b>TGR-63</b>, non-cannabinoid small molecule that has shown promise in pre-clinical trials for reducing amyloid burden in an Alzheimer’s disease model. In Alzheimer’s, the accumulation of beta-amyloid protein in the brain leads to the formation of Aβ plaques, which are associated with neurotoxicity and cell dysfunction, ultimately leading to cell death and cognitive decline. The potential efficacy of TGR-63 lies in its ability to inhibit the aggregation of beta-amyloid. If shown to be safe and efficacious in human trials in reducing the formation of Aβ plaques, this molecule could halt the neurotoxic process caused by beta-amyloid, thereby preventing or treating Alzheimer’s.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i><span style="text-decoration:underline">Over-the-Counter Products</span></i>: We have created a women’s wellness brand, Holief™ available through online channels that are compliant with relevant federal, state, and local laws, and regulations. Holief™ is an all-natural, non-GMO, vegan, line of over the counter (OTC) products aimed at treating menstrual cramps (dysmenorrhea) and premenstrual syndrome (PMS). The products are available online and through Amazon and other online channels. In addition, we sell our product formulations to other companies that market them under their brand. This is the white label part of the OTC business.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Phase 2 Clinical Trial </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Typically, a Phase 2 trial is divided into a Phase 2A and a Phase 2B trial with the former designed to assess dosing requirements and the latter to establish efficacy. In this document, we refer to the trial as Phase 2 and Phase 2B interchangeably. The Company has initiated a Phase 2B protocol titled “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease”. The protocol is powered at 146 Alzheimer’s patients, with half receiving placebo, and is a superiority, parallel group study.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The primary end point is agitation in dementia due to Alzheimer’s disease as rated by the Cohen-Mansfield Agitation Inventory (CMAI) over a six-week period. The Phase 2 trial will also look at eleven exploratory objectives, including changes in anxiety, changes in cognitive processes such as attention, orientation, language, and visual spatial skills as well as memory, changes in depression, delusions, hallucinations, euphoria/elation, apathy, disinhibition, irritability, aberrant motor behavior, sleep disorder, appetite, quality of life, and caregiver burden. In addition, the trial will evaluate the impact of CYP450 polymorphisms and specifically CYP2C9 on each of the NPS and assess any reductions in psychotropic drugs, among others. CYP2C9 ranks amongst the most important drug metabolizing enzymes in humans, as it breaks down over 100 drugs, including nonsteroidal anti-inflammatory all drugs. We seek to understand how various versions of the enzyme act on IGC-AD1. Each participant will receive two doses of IGC-AD1 (b.i.d.) or two doses of placebo per day for six weeks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Business Organization</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of June 30, 2023, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), IGCare LLC, Holi Hemp LLC, IGC Pharma LLC, SAN Holdings LLC, Sunday Seltzer, LLC, Hamsa Biopharma India Pvt. Ltd. And Colombia-based beneficially-owned subsidiary IGC Pharma SAS (formerly Hamsa Biopharma Colombia SAS) (Hamsa). The Company’s fiscal year is the 52- or 53-week period that ends on March 31. The Company’s principal office is in Maryland established in 2005. Additionally, the Company has offices in Washington state, Colombia, and India. The Company’s filings are available on www.sec.gov.</p>
CY2023Q2	igc	Going Concern Policy Policy Textblock GoingConcernPolicyPolicyTextblock	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Going Concern</b></p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, “<i>Presentation of Financial Statements</i>—<i>Going Concern</i>”, which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses and negative cash flows from operations in the near future.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company estimates that its current cash and cash equivalents balance with working capital credit facility and equity investment is sufficient to support operations beyond the twelve months following the date these consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.</p>
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	17000	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	225000	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	107000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53077436	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51616598	shares
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2022Q2	us-gaap	Revenues Revenues	212000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	2091000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2100000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	18000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	550000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	533000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2641000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2651000	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	20000	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	54000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	72000	usd
CY2023Q2	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	15000	usd
CY2023Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	24000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	193000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	262000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	262000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	358000	usd
CY2023Q2	igc	Statutory Advances StatutoryAdvances	21	usd
CY2023Q1	igc	Statutory Advances StatutoryAdvances	25000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	125000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	107000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	630000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	636000	usd
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	549000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	534000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1179000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1170000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	80000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	88000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	96000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	106000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	117000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10172000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10149000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2068000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1936000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8104000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8213000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	137000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	152000	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	27000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	27000	usd
CY2023Q2	igc	Other Advances OtherAdvances	39000	usd
CY2023Q1	igc	Other Advances OtherAdvances	25000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1017000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1003000	usd
CY2023Q2	us-gaap	Payments For Deposits PaymentsForDeposits	140	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	751000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	619000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	131000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	258000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	129000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	133000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	448000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	358000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1459000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1368000	usd
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	48000	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	31000	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	3000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0375	pure
CY2020Q2	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	731000	usd
CY2020Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30Y
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1000	usd
CY2023Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	1000	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	140000	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	3000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	12000000	usd
CY2023Q2	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.01	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q2	igc	Exercised Weighted Average Grant Date Fair Value ExercisedWeightedAverageGrantDateFairValue	0
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	12000000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	21000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	21000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2023Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.06	pure
CY2023Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.12	pure
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53077436	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	igc	Units Outstanding UnitsOutstanding	91472	shares
CY2023Q2	igc	Unit Description UnitDescription	Ten units may be separated into one share of common stock.
CY2021Q1	igc	Sales Agreement Maximum SalesAgreementMaximum	75000000	usd
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3000000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000000	shares
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.3
CY2023Q2	us-gaap	Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares	7000000	shares
CY2023Q2	igc	Weighted Average Price Per Share WeightedAveragePricePerShare	0.7
CY2023Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	5000000	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0264	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0264	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.85	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.85	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4429000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.01
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	4300000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.3
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	192000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.3
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	0	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	8537000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.65
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	150000	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.39
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.3
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	150000	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.39
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.3
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3500000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2023Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1940000	usd
CY2023Q2	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	10000	usd
CY2023Q2	us-gaap	Fair Value Assets And Liabilities Measured On Recurring Basis Gain Loss Included In Earnings FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings	0	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1950000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1723000	usd
CY2023Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	227000	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	3348000	usd
CY2023	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	0	usd
CY2023	us-gaap	Fair Value Assets And Liabilities Measured On Recurring Basis Gain Loss Included In Earnings FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings	0	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	3350000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3196000	usd
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	154000	usd
CY2023Q2	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2023Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2023Q2	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023	us-gaap	Revenues Revenues	212000	usd
CY2023	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2023Q2	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2022Q2	us-gaap	Revenues Revenues	212000	usd
CY2022Q2	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1179000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8104000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1017000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	295000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	10595000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1170000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8213000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1003000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	326000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	10712000	usd
CY2023Q2	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001326205

Files In Submission

Name	View Source	Status
0001185185-23-000796-index-headers.html	Edgar Link	pending
0001185185-23-000796-index.html	Edgar Link	pending
0001185185-23-000796.txt	Edgar Link	pending
0001185185-23-000796-xbrl.zip	Edgar Link	pending
ex_556783.htm	Edgar Link	pending
ex_556784.htm	Edgar Link	pending
ex_556785.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
igc-20230630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
igcpharma20230630_10q.htm	Edgar Link	pending
igcpharma_logo1.jpg	Edgar Link	pending
logo_2sm.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
igc-20230630_pre.xml	Edgar Link	unprocessable
igcpharma20230630_10q_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
igc-20230630_def.xml	Edgar Link	unprocessable
igc-20230630_cal.xml	Edgar Link	unprocessable
igc-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IGC
IGC Pharma Inc Stock $igc

2023 Q3 Form 10-Q Financial Statement

#000118518523000796 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IGC IGC Pharma Inc Stock $igc

2023 Q3 Form 10-Q Financial Statement

#000118518523000796 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IGC
IGC Pharma Inc Stock $igc